Phosphodiesterases as therapeutic targets for respiratory diseases

Haoxiao Zuo; Isabella Cattani-Cavalieri; Nshunge Musheshe; Viacheslav O Nikolaev; Martina Schmidt

doi:10.1016/j.pharmthera.2019.02.002

Phosphodiesterases as therapeutic targets for respiratory diseases

Standard

Phosphodiesterases as therapeutic targets for respiratory diseases. / Zuo, Haoxiao; Cattani-Cavalieri, Isabella; Musheshe, Nshunge; Nikolaev, Viacheslav O; Schmidt, Martina.

In: PHARMACOL THERAPEUT, Vol. 197, 05.2019, p. 225-242.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Zuo, H, Cattani-Cavalieri, I, Musheshe, N, Nikolaev, VO & Schmidt, M 2019, 'Phosphodiesterases as therapeutic targets for respiratory diseases', PHARMACOL THERAPEUT, vol. 197, pp. 225-242. https://doi.org/10.1016/j.pharmthera.2019.02.002

APA

Zuo, H., Cattani-Cavalieri, I., Musheshe, N., Nikolaev, V. O., & Schmidt, M. (2019). Phosphodiesterases as therapeutic targets for respiratory diseases. PHARMACOL THERAPEUT, 197, 225-242. https://doi.org/10.1016/j.pharmthera.2019.02.002

Vancouver

Zuo H, Cattani-Cavalieri I, Musheshe N, Nikolaev VO, Schmidt M. Phosphodiesterases as therapeutic targets for respiratory diseases. PHARMACOL THERAPEUT. 2019 May;197:225-242. https://doi.org/10.1016/j.pharmthera.2019.02.002

Bibtex

@article{47e5300b84c24d33a27086bc5cfdf3ef,

title = "Phosphodiesterases as therapeutic targets for respiratory diseases",

abstract = "Chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD) and asthma, affect millions of people all over the world. Cyclic adenosine monophosphate (cAMP) which is one of the most important second messengers, plays a vital role in relaxing airway smooth muscles and suppressing inflammation. Given its vast role in regulating intracellular responses, cAMP provides an attractive pharmaceutical target in the treatment of chronic respiratory diseases. Phosphodiesterases (PDEs) are enzymes that hydrolyze cyclic nucleotides and help control cyclic nucleotide signals in a compartmentalized manner. Currently, the selective PDE4 inhibitor, roflumilast, is used as an add-on treatment for patients with severe COPD associated with bronchitis and a history of frequent exacerbations. In addition, other novel PDE inhibitors are in different phases of clinical trials. The current review provides an overview of the regulation of various PDEs and the potential application of selective PDE inhibitors in the treatment of COPD and asthma. The possibility to combine various PDE inhibitors as a way to increase their therapeutic effectiveness is also emphasized.",

author = "Haoxiao Zuo and Isabella Cattani-Cavalieri and Nshunge Musheshe and Nikolaev, {Viacheslav O} and Martina Schmidt",

year = "2019",

month = may,

doi = "10.1016/j.pharmthera.2019.02.002",

language = "English",

volume = "197",

pages = "225--242",

journal = "PHARMACOL THERAPEUT",

issn = "0163-7258",

publisher = "Elsevier Inc.",

}

RIS

TY - JOUR

T1 - Phosphodiesterases as therapeutic targets for respiratory diseases

AU - Zuo, Haoxiao

AU - Cattani-Cavalieri, Isabella

AU - Musheshe, Nshunge

AU - Nikolaev, Viacheslav O

AU - Schmidt, Martina

PY - 2019/5

Y1 - 2019/5

N2 - Chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD) and asthma, affect millions of people all over the world. Cyclic adenosine monophosphate (cAMP) which is one of the most important second messengers, plays a vital role in relaxing airway smooth muscles and suppressing inflammation. Given its vast role in regulating intracellular responses, cAMP provides an attractive pharmaceutical target in the treatment of chronic respiratory diseases. Phosphodiesterases (PDEs) are enzymes that hydrolyze cyclic nucleotides and help control cyclic nucleotide signals in a compartmentalized manner. Currently, the selective PDE4 inhibitor, roflumilast, is used as an add-on treatment for patients with severe COPD associated with bronchitis and a history of frequent exacerbations. In addition, other novel PDE inhibitors are in different phases of clinical trials. The current review provides an overview of the regulation of various PDEs and the potential application of selective PDE inhibitors in the treatment of COPD and asthma. The possibility to combine various PDE inhibitors as a way to increase their therapeutic effectiveness is also emphasized.

AB - Chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD) and asthma, affect millions of people all over the world. Cyclic adenosine monophosphate (cAMP) which is one of the most important second messengers, plays a vital role in relaxing airway smooth muscles and suppressing inflammation. Given its vast role in regulating intracellular responses, cAMP provides an attractive pharmaceutical target in the treatment of chronic respiratory diseases. Phosphodiesterases (PDEs) are enzymes that hydrolyze cyclic nucleotides and help control cyclic nucleotide signals in a compartmentalized manner. Currently, the selective PDE4 inhibitor, roflumilast, is used as an add-on treatment for patients with severe COPD associated with bronchitis and a history of frequent exacerbations. In addition, other novel PDE inhibitors are in different phases of clinical trials. The current review provides an overview of the regulation of various PDEs and the potential application of selective PDE inhibitors in the treatment of COPD and asthma. The possibility to combine various PDE inhibitors as a way to increase their therapeutic effectiveness is also emphasized.

U2 - 10.1016/j.pharmthera.2019.02.002

DO - 10.1016/j.pharmthera.2019.02.002

M3 - SCORING: Journal article

C2 - 30759374

VL - 197

SP - 225

EP - 242

JO - PHARMACOL THERAPEUT

JF - PHARMACOL THERAPEUT

SN - 0163-7258

ER -